Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol (original) (raw)
ELEVATED LIPOPROTEIN (a) LEVELS SEEN IN PATIENTS WITH CORONARY ARTERY DISEASE
Prof. Iram Fayyaz
…, 2009
View PDFchevron_right
Lipids in Health and Disease
Teruyoshi Yanagita
2008
View PDFchevron_right
Plasma PCSK9 levels correlate with cholesterol in men but not in women
Majambu Mbikay
Biochemical and Biophysical Research Communications, 2007
View PDFchevron_right
Low High-Density Lipoprotein Cholesterol
Arnold Von Eckardstein
Drugs, 2003
View PDFchevron_right
European Lipoprotein Club: Report of the 28th ELC Annual Conference, Tutzing, 12–15 September 2005
Mats Rudling
Atherosclerosis, 2006
View PDFchevron_right
Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates
Ellen Koehler-stec
Clinical Lipidology, 2012
View PDFchevron_right
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Valgerdur Steinthorsdottir
Journal of the American College of Cardiology, 2019
View PDFchevron_right
High Density Lipoproteins
Arnold Von Eckardstein
Handbook of Experimental Pharmacology, 2015
View PDFchevron_right
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
Angela Ren
Journal of the American College of Cardiology, 2014
View PDFchevron_right
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Nabil G. Seidah
Current Pharmaceutical Design, 2013
View PDFchevron_right
HDL cholesterol is an independent predictor of β‐cell function decline and incident type 2 diabetes: A longitudinal study
Francesco Perticone
Diabetes-metabolism Research and Reviews, 2020
View PDFchevron_right
Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor
Dayami Lopez
Archives of Biochemistry and Biophysics, 2014
View PDFchevron_right
Diseases Associated with Lipid Disorders in Western Region in Kingdom of Saudi Arabi
MANAL MURAD
International Journal of Advanced Research, 2020
View PDFchevron_right
Lipoprotein (a): molecular and epidemiologic basis about its role in cardiovascular diseases
valmore bermudez
Revista …, 2008
View PDFchevron_right
High-density lipoprotein subfractions display proatherogenic properties in overweight and obese children
Colin Boreham
Pediatric Research, 2013
View PDFchevron_right
Epidemiology - cardiovascular outcomes
Rafał Ficek
Nephrology Dialysis Transplantation, 2013
View PDFchevron_right
Elevated Blood Cholesterol
Judith LaRosa
AAOHN Journal, 1990
View PDFchevron_right
Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease
Ole Faergeman
Journal of Internal Medicine, 2006
View PDFchevron_right
Intensively Lowering Both Low-Density Lipoprotein Cholesterol and Blood Pressure Does Not Reduce Cardiovascular Risk in Japanese Coronary Artery Disease Patients
Hiroyuki Daida
Circulation Journal, 2011
View PDFchevron_right
Severity of coronary atherosclerosis related to lipoprotein concentration
Richard W Harper
BMJ, 1978
View PDFchevron_right
Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India
Lipid India
Journal of Clinical Lipidology, 2020
View PDFchevron_right
European Lipoprotein Club: Report of the 35th ELC Annual Conference (Tutzing, 10th–13th September 2012)
Arnold Von Eckardstein
Atherosclerosis, 2013
View PDFchevron_right
Lipids a Triggering Factor Responsible for Coronary Artery Disease in Patients with Type 2 Diabetes
Sanjay Swami
International journal of scientific research, 2019
View PDFchevron_right
7-Ketocholesterol in disease and aging
Amelia Anderson
Redox Biology, 2019
View PDFchevron_right
Low Cholesterol and Increased Risk
Vincenzo Neri
The Lancet, 1989
View PDFchevron_right
European Lipoprotein Club: Report of the 34th ELC annual conference, Tutzing, 5–8 September 2011
Monique Mulder
Atherosclerosis, 2012
View PDFchevron_right
Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]
Zlatko FRAS
Atherosclerosis, 2019
View PDFchevron_right
n−3 Fatty acids and the metabolic syndrome
Yvon Carpentier
The American Journal of Clinical Nutrition, 2006
View PDFchevron_right
Atherogenesis and the humoral immune response to modified lipoproteins
Maria Lopes-virella
Atherosclerosis, 2008
View PDFchevron_right
Changes in plasma high-density lipoprotein cholesterol concentration after weight reduction in grossly obese subjects
Simon Rabkin
BMJ, 1980
View PDFchevron_right
Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor
Günay Can
Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology, 2013
View PDFchevron_right
Hubungan Asupan Energi, Lemak Dan Serat Dengan Rasio Kadar Kolesterol Total-HDL
Ayu Pravita Sari
Penelitian Gizi dan Makanan (The Journal of Nutrition and Food Research), 2016
View PDFchevron_right
High fat diet modifies the association of lipoprotein lipase gene polymorphism with high density lipoprotein cholesterol in an Asian Indian population
Dhanasekaran Bodhini
Nutrition & Metabolism, 2017
View PDFchevron_right
Treating Hyperlipidemia for the Primary Prevention of Coronary Disease
Sylvie Perreault
Archives of internal medicine, 1998
View PDFchevron_right
Lipoprotein (a) and aortic valve calcium in South Asians compared to other race/ethnic groups
Alka Kanaya
Atherosclerosis, 2020
View PDFchevron_right